Johnson & Johnson (JNJ) October 160 straddle priced into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street rises on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Johnson & Johnson (JNJ) PT Raised to $181 at RBC Capital
October 16, 2024 6:50 AM EDTRBC Capital analyst Shagun Singh raised the price target on Johnson & Johnson (NYSE: JNJ) to $181.00 (from $178.00) while maintaining a Outperform rating.
The analyst comments "JNJ delivered a Q3 beat on sales/EPS that sent the stock up ~2% today. The company delivered +5.6% y/y underlying... More
Johnson & Johnson (JNJ) PT Raised to $170 at Stifel
October 15, 2024 2:22 PM EDTStifel analyst Rick Wise raised the price target on Johnson & Johnson (NYSE: JNJ) to $170.00 (from $160.00) while maintaining a Hold rating.
The analyst comments "Helped by better-than-expected 3Q24 Pharmaceutical division performance, both JNJ 3Q24 sales and EPS outperformed Stifel and consensus. And looking ahead, the company's... More
Citi Reiterates Buy Rating on Johnson & Johnson (JNJ)
October 15, 2024 8:20 AM EDTCiti analyst Joanna Wuensch reiterated a Buy rating and $180.00 price target on Johnson & Johnson (NYSE: JNJ).
The analyst comments "JNJ delivered 3Q24 revenue of $22.5B (up 5.6% organic) ahead of consensuss $22.2B. Innovative Medicine sales were $14.58B (up 6.7% organic ex-Covid-19, versus consensuss... More

